Tracking China

Behind Loncar’s new China biopharma ETF

Despite launching amidst a dour market, investor Brad Loncar expects his new exchange-traded fund, the Loncar China BioPharma ETF (NASDAQ:CHNA), to see significant long-term growth.

The ETF, which finished the week down $0.32 to $23.47 since it began trading on Wednesday, tracks the Loncar China BioPharma Index (LCHINA). Loncar launched LCHINA on March 14

Read the full 536 word article

User Sign In